The outbreak of invasive fungal infections among patients who received injections of contaminated methylprednisolone acetate from the New England Compounding Center continues.
New cases have been reported to the Centers for Disease Control and Prevention weekly and more than 740 patients in 20 states have been diagnosed with meningitis, spinal or paraspinal infections, or joint infections (ie, epidural abscess, phlegmon, diskitis, vertebral osteomyelitis, arachnoiditis, or other complications at or near the injection site).1